DarshanTalks Podcast

Darshan Kulkarni
  • 0.0 (0)
  • Life Sciences
  • Updated Semiweekly

Welcome to DarshanTalks! We demystify fraud for legal, regulatory, and compliance essentials in the life sciences and pharmacy industries. Through engaging 15-30-minute interviews with influential change makers, short educational regulatory defbriefs, and 60 second audio takeaways, we unveil the strategies behind bringing drugs and devices to market—and keeping them there! Powered By The Kulkarni Law Firm -  Helping regulators see your business the way you do. We focus on life science issues involving medical affairs, marketing and advertising, and clinical research so that you can learn about the industry, enhance your business and grow your career. 

  1. 1d ago

    Pharmacy's Critical Role in Clinical Trial Compliance

    Send us Fan Mail Think clinical trial compliance is just a part-time job or a paperwork exercise that can be passed off to a medical assistant? Think again. In this episode of the KF Deep Dive, host Daran Carney sits down with Tom Sepka, CEO of HCI Healthcare Consultants and veteran Chief Pharmacy Officer, to shatter the myth that research pharmacy oversight is optional. Together, they break down the deep operational complexities of managing investigational drugs—from navigating strict DEA registrations and state licensures to enforcing rigorous recordkeeping, environmental controls, and USP compounding regulations. Tom shares first-hand insights on how failing to build a dedicated pharmacy infrastructure directly threatens a trial's integrity, invites regulatory scrutiny, and increases liability for principal investigators. Whether you are running a large academic medical center or a scaling community research site, this conversation reveals the exact guardrails needed to keep your protocols tight, your data compliant, and your proprietary assets legally sound. What You'll Learn in This Episode: FTE Realities: How to determine the exact pharmacy staffing requirements (from 1 to multiple FTEs) based on the size and scope of your clinical trials.The Pitfalls of Delegation: Why leaving investigational drug inventory, blinding, and randomization to non-pharmacy staff is an immense regulatory gamble.Complex Controls: Navigating the layers of state boards, the FDA, USP 797, and the DEA—especially in emerging research spaces like psychedelics and cannabis.End-of-Life Protocols: The standard practices for handling drug disposal and reverse distribution when sponsors go dark or trials close.Support the show www.kulkarnilawfirm.com

    Pharmacy's Critical Role in Clinical Trial Compliance

  2. Jul 8

    The Wild Lizard Venom Origins of Ozempic

    Send us Fan Mail How a "Failed" 4-Minute Molecule Created a Trillion-Dollar Cultural Eclipse Imagine pitching a drug to a room of venture capitalists that is biologically perfect—except for one tiny flaw: the human body completely destroys it in four minutes flat. That is the exact garbage hand Danish pharma giant Novo Nordisk was dealt in the 1990s. Today, that exact same molecule is Ozempic and Wegovy, a global phenomenon reshaping culture, tech, Hollywood, and global economies. But how did a failed diabetes drug become a trillion-dollar empire? In this episode, we break down the masterclass of corporate judo that made it happen. It wasn't just a scientific miracle; it was a perfect storm of genius bio-hacking, cutthroat business strategy, a regulatory game of chess with the FDA, and a brilliant, bulletproof legal wall that let the Hollywood whisper network do the marketing for them. Tune in to discover how science built the engine, business funded the track, regulators set the boundaries, and the lawyers drove the train straight into a multi-billion-dollar gold mine—and what the rise of compounding pharmacies means for the future of generic Ozempic. Support the show www.kulkarnilawfirm.com

    The Wild Lizard Venom Origins of Ozempic

  3. May 18

    Unlicensed Medical Advice & The Legal Battle Over Character.AI

    Send us Fan Mail What happens when an artificial intelligence chatbot generates a fake medical license number and starts giving psychiatric advice? In this episode of the KF Deep Dive, host Darshan welcomes healthcare regulatory expert and Fox Rothschild Chief Privacy Officer, Elizabeth Litten, to untangle a wild new frontier in legal tech. We break down the historic lawsuit filed by Pennsylvania Governor Josh Shapiro against Character.AI after a companion bot unlawfully held itself out as a licensed physician. Darshan and Elizabeth pull back the curtain on the critical compliance flaws of generative AI in healthcare. From the "overwarning" dilemma in Electronic Medical Record (EMR) systems to the dangerous lack of human oversight and clinical judgment, this conversation highlights why letting AI act as a "black box" diagnostic tool is a massive liability risk. Tune in as they discuss: The Character.AI Lawsuit: Why the state of Pennsylvania is cracking down on AI bots posing as licensed mental health professionals.The "Level 1" Error Problem: How software developers shift malpractice liability onto clinicians by forcing endless, low-level warning click-throughs.Consent & The Ambient AI Trap: The hidden dangers of data-scraping, the illegality of selling Protected Health Information (PHI) under HIPAA, and why doctors must get explicit patient consent before using AI note-taking tools.AI Governance Guidelines: Elizabeth’s top 3 compliance strategies for companies looking to safely deploy AI characters and automated tools without facing massive legal repercussions.Whether you are a healthcare professional, a software developer, or just fascinated by the intersection of law and cutting-edge technology, this episode is a must-listen guide to navigating the untamed wild west of AI. Support the show www.kulkarnilawfirm.com

  4. May 6

    Sponsoring Cannabis Research

    Send us Fan Mail  NOT LEGAL ADVICE  For decades, cannabis research in the U.S. was stifled by Schedule I restrictions, requiring high-security vaults, mountains of paperwork, and extremely limited supply chains. With Executive Order 14370, the landscape has shifted. Marijuana is moving to Schedule III, and the rules of the game have officially changed. In this episode of KLF Deep Dive, attorney-pharmacist Darshan Kulkarni breaks down the practical impact of this reclassification for clinical trial sponsors. We move beyond the headlines to discuss the "pharmacy-style" compliance now required and the hidden pitfalls of using non-pharmacist staff at trial sites. Key Topics Covered: The Security Shift: Why you can ditch the steel vaults, but why your new "pharmacy" status brings a different set of DEA headaches.Supply Chain Normalization: Moving away from the "one-plant" monopoly toward a traditional pharma infrastructure.The Real-World Evidence (RWE) Invitation: How the FDA is encouraging the use of patient records and "real-world stories" to prove efficacy.The Compliance Trap: Why vetting your trial sites’ staffing—specifically the use of CRNAs vs. Pharmacists—is now a top-tier regulatory risk.Targeting Federal Grants: Why studies focusing on veterans and the elderly are currently "first in line" for federal support.The Bottom Line: The federal government has moved from stopping research to starting it. But as a sponsor, your site list just got bigger—and so did your responsibility to ensure they aren't just pretending to be compliant. Support the show: www.kulkarnilawfirm.com Support the show www.kulkarnilawfirm.com

  5. Apr 30

    The New Era of Personal Consent Decrees

    Send us Fan Mail Is your career protected from your company’s mistakes? For decades, a Federal Consent Decree was a corporate headache. Today, it’s a personal professional death sentence. In this episode, Darshan Kulkarni breaks down the seismic shift in federal enforcement: why agencies are now naming CEOs, CMOs, and Heads of Clinical operations by name in injunctions. We explore the "Delegation Trap," the rise of the Office of Data Reliability, and the KLF Playbook for ensuring your name never appears on a federal blackball list.  Support the show www.kulkarnilawfirm.com

  6. Apr 16

    Why Private Membership Associations Fail FDA Scrutiny

    Send us Fan Mail  In this episode of the KLF Deep Dive, Darshan Kulkarni deconstructs a persistent and dangerous myth circulating in life sciences and investment circles: the Private Membership Association (PMA). While often marketed as a "contract-based loophole" to evade FDA oversight and civil liability, the reality in federal court is starkly different. Darshan examines the constitutional limits of "freedom of association" and analyzes key case law—including Little v. Q Lasers—to demonstrate why PMAs are viewed by judges as red flags rather than legal shields. If you are advising clients on regulatory shortcuts, this is a must-listen briefing on maintaining professional integrity and statutory compliance.  Support the show www.kulkarnilawfirm.com

  7. Apr 11

    The Hidden Reason Sites are Firing Recruiters

    Send us Fan Mail  What would happen if your clinical trial sites were suddenly banned from using you? In this episode, Darshan Kulkarni uncovers a hidden regulatory shift: state licensing boards are tightening the "Corporate Practice of Medicine" and "Fee Splitting" laws. If your recruitment fees are tied to enrollment or revenue, you aren't just a vendor—you’re a legal liability. We break down the MSO structures that are failing, the "Red Zones" in state law, and how KLF re-architects your contracts to make you the safest, most scalable partner in the life sciences industry.  Support the show www.kulkarnilawfirm.com

  8. Apr 10

    Don’t Let Your PI Walk Away With Your Study

    Send us Fan Mail  In this tactical masterclass, Darshan Kulkarni breaks down the critical legal architecture required to protect clinical trial sites during rapid expansion. As PIs and Sub-Investigators move between organizations, the risk of losing proprietary data and patient continuity skyrockets. Learn the specific clauses—from non-solicitation to transition requirements—that ensure your site retains its value and your sponsors remain confident. Don't let your most valuable assets walk out the door; learn how to lock down your contracts today.  Support the show www.kulkarnilawfirm.com

See All (347)

About

Welcome to DarshanTalks! We demystify fraud for legal, regulatory, and compliance essentials in the life sciences and pharmacy industries. Through engaging 15-30-minute interviews with influential change makers, short educational regulatory defbriefs, and 60 second audio takeaways, we unveil the strategies behind bringing drugs and devices to market—and keeping them there! Powered By The Kulkarni Law Firm -  Helping regulators see your business the way you do. We focus on life science issues involving medical affairs, marketing and advertising, and clinical research so that you can learn about the industry, enhance your business and grow your career. 

Information

  • Creator
    Darshan Kulkarni
  • Years Active
    2023 - 2026
  • Episodes
    347
  • Rating
    Clean
  • Copyright
    © 2026 DarshanTalks Podcast
  • Show Website
    DarshanTalks Podcast